Facilitated group support for Endometrial Neoplasms

Phase-Based Progress Estimates
Endometrial Neoplasms+2 More
Facilitated group support - Behavioral
What conditions do you have?

Study Summary

This trial is looking at whether social support can help Black patients with endometrial cancer finish their treatment.

Eligible Conditions
  • Endometrial Neoplasms
  • Endometrial Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Endometrial Neoplasms

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 6 months

6 months
Patient-reported social isolation (SPS-24)
Treatment completion (relative dose)

Trial Safety

Safety Progress

1 of 3

Other trials for Endometrial Neoplasms

Trial Design

3 Treatment Groups

Enhanced usual care
1 of 3
Facilitated group support
1 of 3
1:1 Peer Support
1 of 3
Active Control

252 Total Participants · 3 Treatment Groups

Primary Treatment: Facilitated group support · No Placebo Group · N/A

Enhanced usual careNoIntervention Group · 1 Intervention: Enhanced usual care · Intervention Types:
Facilitated group support
ActiveComparator Group · 1 Intervention: Facilitated group support · Intervention Types: Behavioral
1:1 Peer Support
ActiveComparator Group · 1 Intervention: 1:1 Peer Support · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,583 Previous Clinical Trials
1,565,734 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
492 Previous Clinical Trials
29,827,423 Total Patients Enrolled
Kemi M Doll, MD, MSPrincipal InvestigatorUniversity of Washington

Eligibility Criteria

Age 18+ · Female Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You self-identify as Black/African American.
Documentation of any medical condition, disease, or disorder.
You have a FIGO stage 1B, 2, 3, or 4 of any grade or histology.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.